Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ES009 |
| Synonyms | |
| Therapy Description |
ES009 is a monoclonal antibody that targets LILRB2 (ILT4), which may promote a pro-inflammatory state and increase anti-tumor immune response (Journal for ImmunoTherapy of Cancer 2022;10). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ES009 | ES 009|ES-009 | LILRB2 Antibody 12 | ES009 is a monoclonal antibody that targets LILRB2 (ILT4), which may promote a pro-inflammatory state and increase anti-tumor immune response (Journal for ImmunoTherapy of Cancer 2022;10). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06007482 | Phase I | ES009 | A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors | Completed | AUS | 0 |